Kadans expands relationship with Oxford Biomedica through Harrow House purchase

London, July 3rd - Kadans Science Partner will add Harrow House in Oxford, UK to its Pan-European portfolio. The asset will be acquired from Oxford Biomedica in a sale and lease back transaction. Harrow House is a purpose-built manufacturing facility which will be leased back, in its entirety, to Oxford Biomedica. Oxford Biomedica is a quality and innovation-led viral vector CDMO, providing development and manufacturing expertise to some of the world’s most innovative pharmaceutical and biotechnology companies. 

Oxford is a global centre of excellence in life science innovation. The cluster is anchored by the University of Oxford which was recently named the number 1 university in the world (Times World University Ranking 2022). The Oxford cluster spans a whole range of life sciences enterprise including drug discovery, diagnostics, medical devices, regenerative medicine and genomics. With world leading academics, researchers and clinicians Oxford continues to be at the forefront of scientific innovation. 

James Sheppard, Managing Director (UK & Ireland) said: ‘We are pleased to be continuing to build our relationship with Oxford Biomedica. Harrow House has long played an important role for Oxford Biomedica and we look forward to working with them on the next stage of its evolution.’ 

Nick Page, Chief Operations Officer at Oxford Biomedica said: “We welcome this opportunity to broaden our ongoing relationship with Kadans. This transaction enables us to maximise value from our earlier investment and assists with future growth opportunities as we build our position as a quality and innovation-led viral vector CDMO.  

With the acquisition of Harrow House, Oxford, the Kadans portfolio now comprises of over 65 buildings and numerous projects under development in the Netherlands, United Kingdom, Germany, Belgium, France and Spain. Kadans aspires to partner with universities, venture capital firms and innovative organisations to create one strong knowledge-sharing ecosystem of scientific enterprise across Europe. 

Kadans was supported in this transaction by Knight Frank and Mills & Reeve acted as legal advisors for Kadans. Plainlaw acted as legal advisors to Oxford Biomedica. 

About Kadans Science Partner 

Kadans Science Partner is the European leader investing in the development of ecosystems and real estate with a dedicated focus on the knowledge intensive sector. Kadans has invested across various specific areas, like agri-tech in Wageningen, life sciences in Leiden, and cell & gene therapy in Stevenage, UK. Kadans provides its tenants with an array of additional services tailored to their specific needs. In December 2020, Kadans was acquired by AXA IM Alts, which, as a long- term capital partner, has allowed us to significantly accelerate our growth. 

Kadans is currently present on 28 campuses, in 6 countries, where it operates over 8 million sq ft of space for over 450 tenants, including start-ups, scale-ups, corporates, government bodies and educational institutes. Kadans has a solid view of the developments our tenants and partners are currently working on and which parties in our network could benefit from connecting. 


About Oxford Biomedica 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube

Media Contact Information: 

Jullianne Power
Team Lewis